Rapid Micro Biosystems

Rapid Micro Biosystems is a leader in automated detection of microbial contamination, primarily serving the pharmaceutical and biomanufacturing sectors. Headquartered in Lowell, Massachusetts, the company also has manufacturing operations in the U.S. and locations in Switzerland, Germany, and the Netherlands. Their mission focuses on enhancing microbial quality control processes through advanced automation and data integrity. The flagship product, the Growth Direct® System, is the first fully automated growth-based platform for traditional microbial testing. This system is designed for critical applications such as environmental monitoring, water testing, bioburden testing, and rapid sterility testing. It offers faster contamination detection, improved data integrity, and reduced operational risks, ultimately accelerating manufacturing timelines and increasing efficiency. Rapid Micro Biosystems caters to a diverse range of industries, including pharmaceuticals, biotechnology, medical devices, and personal care products. The company is particularly well-suited to support cell and gene therapies, which require rigorous microbial quality control. Recent funding of $81 million highlights the company's growth potential and strong market position.